|
Introduction of Idarubicin
Idarubicin belongs to a general group of chemotherapy drugs
known as anthracycline antibiotics. It is used to treat
nonlymphocytic leukemia in combination with other drugs.
Idarubicin prevents cells from making DNA and/or RNA, thus
altering cell growth. Idarubicin is given as an injection in
the vein over about 15 minutes. Tell the nurse if you feel
pain, burning, or discomfort in the vein when it is given. You
will get medicine to stop any nausea or vomiting before the
idarubicin and to take afterward. The dose and how often you
get the medicine depends upon your size, your blood counts,
how well your liver is working, and the type of cancer being
treated. You will have your blood counts checked before each
treatment. If they are too low, your treatment will be
delayed. This medicine may be given in addition to other
chemotherapy medicines.
Before using
Idarubicin, tell your doctor
-
If you are trying to become pregnant, are
pregnant, or breastfeeding. This drug may cause birth
defects if either the male or female is taking it at the
time of conception or during pregnancy. Men and women who
are taking this drug need to use some kind of birth control.
However, do not use oral contraceptives (“the pill”) without
checking with your doctor.
-
If you think you may want to have children in
the future. Many chemotherapy drugs can cause sterility.
-
If you have any of the following medical
problems: chickenpox or exposure to chickenpox, gout, heart
disease, congestive heart failure, shingles, kidney stones,
liver disease, or other forms of cancer.
-
If you are taking any other prescription or
over-the-counter drugs, including vitamins and herbals.
Precautions while taking Idarubicin
While you are being treated with idarubicin, and after you
stop treatment, do not have any immunizations (vaccinations)
without your doctor’s okay. Try to avoid contact with people
who have recently taken the oral polio vaccine. Check with
your doctor about this.
Idarubicin can lower your blood counts (white blood cells, red
blood cells, platelets). Your doctor will check your blood
counts before and after each treatment to see how it affects
your blood counts. Your doctor or nurse will give you specific
instructions if your blood counts are low.
Idarubicin can decrease your white blood cell count,
especially 10 to 20 days after the drug is given. This can
increase your risk of getting an infection. Report fever of
100.5°F or higher, or signs of infection such as pain in
passing your urine, coughing, and bringing up sputum.
Idarubicin can decrease the platelet count. This can increase
your risk of bleeding. DO NOT take any aspirin or
aspirin–containing medicines. Report unusual bruising, or
bleeding such as nosebleeds, bleeding gums when you brush your
teeth, or black, tarry stools.
Idarubicin is given in a vein. If the drug accidentally leaks
out of the vein where it is given, it can damage the tissue
and cause scarring. Tell the nurse right away if you notice
redness, pain, or swelling at the place of injection.
Idarubicin can injure the heart muscle when large doses are
given. Your doctor will test your heart function before you
receive your first treatment, and then during the treatment.
This way, any damage can be found early. Talk to your doctor
about this.
Getting a wig before starting treatment may make it easier to
deal with hair loss. Talk to your nurse or doctor about this.
If your insurance does not cover it, there may be other
resources to help you. Hair loss is temporary, and your hair
will grow back after treatment.
Idarubicin can cause severe nausea and vomiting. Ask your
doctor or nurse to give you medicines to prevent or lessen
this.
Side
effects of Idarubicin
-
Decreased white blood cell count with increased risk of
infection
-
Decreased platelet count with increased risk of bleeding
-
Nausea
-
Vomiting
-
Decreased appetite
-
Sores in
mouth or on lips
-
Hair
loss
-
Skin Rash
-
Darkening of nail beds
-
Abnormal
liver function blood tests
-
Diarrhea
-
Inflammation of the liver
-
Heart damage with congestive heart failure
Disclaimer:
Information on this page is provided for general
information purposes. You should not make a clinical treatment
decision based on information contained in this page without
consulting other references including the package insert of
the drug, textbooks and where relevant, expert opinion. We
cannot be held responsible for any errors you make in
administering drugs mentioned on this page, nor for use of any
erroneous information contained on this page.
|